OBJECTIVES The aim of this study was to assess the impact of ticagrelor dosing regimens on pharmacodynamic (PD) profiles in patients on maintenance ticagrelor therapy.
. In a large-scale clinical trial of ACS patients, ticagrelor was associated with a significant reduction in ischemic events, including cardiovascular mortality, compared with clopidogrel at 12 months (8) . Such benefit was observed irrespective of management strategy (invasive or noninvasive) and occurred without any differences in overall major bleeding complications, although noncoronary artery bypass graft bleeding events were increased with ticagrelor. Despite such benefit, recurrent atherothrombotic events still occur in ticagrelor-treated patients who may also require PCI (8, 9) . Moreover, many patients receiving maintenance ticagrelor therapy may need revascularization because of coronary atherosclerotic disease progression or for staged PCI (10, 11) .
Numerous investigations have been conducted to define the dosing regimen associated with more favorable PD effects in patients on maintenance P2Y 12 -inhibiting therapy using thienopyridines (12) (13) (14) (15) (16) (17) . In particular, reloading patients on maintenance clopidogrel therapy is associated with additional platelet inhibition (12) (13) (14) . This was also demonstrated among prasugrel-treated patients, suggesting that a sizable number of P2Y 12 receptors remain uninhibited during maintenance therapy even with a more potent agent (15, 16) . However, there are substantial differences in the pharmacological properties between ticagrelor and thienopyridines (4-7), and whether PD profiles vary according to the dosing regimen administered in patients on maintenance ticagrelor therapy remains unexplored. Therefore, we conducted a study to assess the PD effects of different ticagrelor dosing regimens in patients on ticagrelor maintenance therapy.
METHODS STUDY POPULATION AND RESEARCH DESIGN.
This was a prospective, randomized, double-blind, placebo-controlled PD study conducted in patients on maintenance ticagrelor therapy (NCT01731041).
All patients had experienced an ACS and a guidelinebased indication to be on DAPT with aspirin and ticagrelor (1-3). Patients were screened at the Division of Cardiology of the University of Florida College of Medicine -Jacksonville. All patients were eligible for the study if they were between 18 and 80 years of age and if they were receiving treatment with low-dose aspirin (<100 mg/day) and ticagrelor (90 mg/bid) for at least 14 days as part of their standard treatment regimen. Exclusion criteria included history of intracranial bleeding, severe hepatic impairment (hepatic enzymes >2. 5 Blood samples were collected at 3 time points at baseline (while on maintenance ticagrelor therapy)
and at 1 h and 4 h after randomized treatment.
Baseline blood samples were collected 12 AE 2 h after Cho et al.
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SAMPLE SIZE CALCULATION AND STUDY ENDPOINTS.
The primary endpoint of the study was the comparison in the PRI determined by VASP between baseline and 4 h after dosing in each arm of treatment.
Assuming an absolute 10% difference in VASP-PRI between baseline and 4 h with a common SD of 14%, 28 patients need to be enrolled in each arm to obtain a 95% power and a 2-sided alpha of 0.05.
Considering a possible dropout rate of w5% to 10%, we estimated that a total of 60 patients needed to be randomized to ensure that complete data would be available for analysis. A cutoff of 10% absolute change in PRI was chosen because this has been associated with a 44% relative reduction of thrombotic events in patients undergoing PCI (19) . Additional analysis assessing intergroup and intragroup PD differences using the VN-P2Y12 and LTA were also conducted. Figure 1 . Baseline characteristics of the study population are summarized in Table 1 .
There were no differences in baseline characteristics between groups. No adverse events were reported.
PHARMACODYNAMIC FINDINGS. Values are mean AE SD, n (%), or median (interquartile range). *All patients on aspirin 81 mg/day and ticagrelor 90 mg twice daily. †Most (91.7%) patients treated with PCI at time of acute coronary syndrome presentation; 8.3% of patients medically managed after undergoing invasive evaluation. ‡Time frame between first ticagrelor dose after the acute event and first study blood draw.
ACEI/ARB ¼ angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; BMI ¼ body mass index; CCB ¼ calcium channel blocker; LVEF ¼ left ventricular ejection fraction; PCI ¼ percutaneous coronary intervention; PPI ¼ proton pump inhibitor.
Cho et al. STUDY LIMITATIONS. This investigation was powered to assess intragroup comparisons but not intergroup comparisons. Therefore, the latter results should be considered as exploratory. In addition, our study was conducted in patients who were clinically stable after experiencing an ACS and not in patients undergoing PCI who may therefore share different PD profiles. Moreover, our study was not powered to assess safety or efficacy, which would require larger clinical studies. Hence, the lack of adverse events, including bleeding complications (e.g., arterial access site complications), in this study should be interpreted with caution. 
